<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200105046009N7</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-09</date_registration>
      <primary_sponsor>Babol University of Medical Sciences</primary_sponsor>
      <public_title>The effect of topical chamomile herbal product on the symptoms of patients with muscle cramps</public_title>
      <acronym></acronym>
      <scientific_title>The effect of topical chamomile herbal product on the symptoms of patients with leg cramps in comparison with standard treatment: a double-blind clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>64</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67879</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be done using the permuted block randomization method. The size of the blocks is 4 and the ratio of drug to control (diclofenac gel) in each group is equal to (1:1).
In each block, random permutations of 4 combinations of chamomile formulation and diclofenac gel are considered. Random sequence generation will be done by the design methodologist.
In order to hide the treatment process, random codes are written on the boxes containing medicine (chamomile product/diclofenac) and after assigning the medicine to the patients, the corresponding code is recorded on the patients' files. The opening of the codes will be done after the end of the study. In case of side effects, the code of that medicine will be opened, Blinding description: Chamomile product and diclofenac gel in a single form, with the same label and the same smell and color (with the addition of color and essential oil) will be prepared by a pharmaceutical specialist in the medicinal plant laboratory of the Faculty of Iranian Medicine in Babol. The only person who knows the nature of drugs is the pharmacist who makes the drug.</study_design>
      <phase>3</phase>
      <hc_freetext>muscle cramp.</hc_freetext>
      <i_freetext>Intervention 1: Chamomile topical product (combination of chamomile oil and wax made in the laboratory of the Iranian Faculty of Medicine) in the amount of one knuckle every eight hours is used topically on the leg muscles and the VAS index, before the intervention and on even days after The start of the intervention is measured and the treatment continues until the pain index reaches 4 or a change of 1.7 based on the MCID. Intervention 2: 1% diclofenac gel of Soban company is used topically on the calf muscles in the amount of one knuckle every eight hours, and the VAS index is measured before the intervention and on even days after the intervention, and the treatment is continued until the day the pain index is reached. Continued to number 4 or a rate of change of 1.7 based on MCID.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyyed Ali Mozaffarpur</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Traditional Persian Medicine, Babol University of Medical Sciences, Ganjafruz Ave, Babol</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۷۱۷۶-۴۷۷۴۵</zip>
        <telephone>+98 11 3219 4728</telephone>
        <email>dr.mozaffarpur@mubabol.ac.ir</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyyed Ali Mozaffarpur</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Traditional Persian Medicine, Babol University of Medical Sciences, Ganjafruz Ave, Babol</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۷۱۷۶-۴۷۷۴۵</zip>
        <telephone>+98 11 3219 4728</telephone>
        <email>dr.mozaffarpur@mubabol.ac.ir</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Men and women aged 20 to 60 years
Presence of muscle cramp in the gastrocnemius muscle
The presence of pain with a vas score greater than six</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Lack of complete evaluation to monitor the treatment process
Lack of satisfaction during treatment
The presence of underlying diseases related to cramps
Using other painkillers
Performing procedures that lead to the improvement of muscle cramps
History of recurrent cramps without clear cause</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R25.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Cramp and spasm</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Chamomile topical product (combination of chamomile oil and wax made in the laboratory of the Iranian Faculty of Medicine) in the amount of one knuckle every eight hours is used topically on the leg muscles and the VAS index, before the intervention and on even days after The start of the intervention is measured and the treatment continues until the pain index reaches 4 or a change of 1.7 based on the MCID.</i_keyword>
      <i_keyword>1% diclofenac gel of Soban company is used topically on the calf muscles in the amount of one knuckle every eight hours, and the VAS index is measured before the intervention and on even days after the intervention, and the treatment is continued until the day the pain index is reached. Continued to number 4 or a rate of change of 1.7 based on MCID</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain index. Timepoint: The VAS measurement is measured before the intervention and on even days after the start of the intervention, and the treatment continues until the pain index reaches 4 or a change of 1.7 based on the MCID. Method of measurement: Pain intensity measurement using VAS tool.</prim_outcome>
      <prim_outcome>Duration of treatment. Timepoint: VAS is measured before the intervention and on even days after the start of the intervention, and the examination of the pain index continues until the day it reaches the number 4 or the change rate of 1.7 based on the MCID. Method of measurement: Pain intensity measurement using VAS tool.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Redness. Timepoint: Measurements are taken before the intervention and on even days after the start of the intervention, and the treatment continues until the pain index reaches 4 or a change of 1.7 based on the MCID. Method of measurement: By patient report or evaluator observation.</sec_outcome>
      <sec_outcome>Itching. Timepoint: Measurements are taken before the intervention and on even days after the start of the intervention, and the treatment continues until the pain index reaches 4 or a change of 1.7 based on the MCID. Method of measurement: By patient report or evaluator observation.</sec_outcome>
      <sec_outcome>Swelling. Timepoint: Measurements are taken before the intervention and on even days after the start of the intervention, and the treatment continues until the pain index reaches 4 or a change of 1.7 based on the MCID. Method of measurement: By patient report or evaluator observation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Babol University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-01-02</approval_date>
        <contact_name>Ethics committee of Babol University of Medical Sciences</contact_name>
        <contact_address>Babol University of Medical sciences, Sargord Ghasemi avenue, Babol Babol Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
